Highlight
- Rentosertib is the first AI-discovered small-molecule inhibitor targeting TNIK, a novel pathway in idiopathic pulmonary fibrosis (IPF).
- The phase 2a multicenter, double-blind, randomized placebo-controlled trial showed rentosertib to be safe and well tolerated over 12 weeks.
- At the highest dose (60 mg once daily), rentosertib improved forced vital capacity (FVC), suggesting potential to attenuate lung function decline.
- These results validate the use of generative AI in identifying new therapeutic targets and compounds for difficult-to-treat diseases like IPF.
Study Background and Disease Burden
